Form 4 Filing for AIM ImmunoTech Inc.

David I. Chemerow, a director at AIM ImmunoTech Inc., reported a series of transactions on March 12, 2026. He acquired 25,000 shares of Common Stock through a conversion of Series G Convertible Preferred Stock. This conversion was valued at an effective price of $1.00 per share of common stock, as indicated by footnote F1. Following these transactions, Mr. Chemerow directly owns 28,441 shares of Common Stock. The filing, marked as Form 4, was signed on March 16, 2026, and pertains to the ownership of securities.